In The News
Research Article: Study Data Shows Technology Effectiveness on Cybersickness from VR
Original research article published by Frontiers, a top peer-reviewed scientific journal.
Otolith Labs' AAO 2024 Booth Attracts Hundreds of Clinicians
Our team had the pleasure of connecting with hundreds of clinicians, strategics, and potential users in the vestibular field and community.
AcuityMD Flywheel 2024: Otolith's Commercial Team First Attendance
“Event where commercial MedTech leaders come together to learn how to stay ahead of market trends & build a high-performance company.“
Founder and CEO Sam Owen Attends LSI Europe 2024
Sam Owen connected with leading innovators, strategics and investors at LSI (Life Science Intelligence) Europe 2024, Metech’s premier partnering event, in Sintra, Portugal.
Otolith Joins VeDA's Industry Advisory Council
“The newly formed IAC brings together organizations that support vestibular healthcare, offering strategic advice to VeDA’s leadership to enhance patient care & advocacy efforts.”
Executive Team Attends The 2024 Bárány Society Meeting in Sweden
Successful meeting hosted by the Barany Society, a society devoted to the study of the vestibular system.
Otolith Labs Rounds Out Executive Team with Hiring of Chief Clinical Officer
Kevin Franck, PhD, MBA appointed as Otolith Labs’ Chief Clinical Officer.
Otolith Expands Leadership Team with CCO and New Board Member
Otolith appointed Dan Wagner as Chief Commercial Officer and Raphael Michel to Otolith’s Board of Directors.
Mark Cuban-Backed Otolith Labs Just Raised Another $20M
Technical.ly interviews Otolith’s CEO Sam Owen about the pressing need for a new treatment option for chronic vertigo.
Business Insider Interviews Otolith CEO Sam Owen About Series A Financing
Otolith’s CEO Sam Owen sat down with Insider to discuss Otolith’s $20 million Series A financing.
Otolith Labs Finds Footing With $20M For Vertigo-Treating Wearable
Fierce Medtech discusses Otolith Labs’ Series A financing and the clinical development of Otolith technology.
Otolith Receives Breakthrough Device Designation from FDA
Otolith Labs announces closing of $3.3 Million in seed funding, as well as receiving “Breakthrough Device” Designation from FDA.
Deals Of The Week: Otolith Raised $20 Million In Series A Financing Round
Forbes features Otolith Labs’ $20 million Series A financing in “Deals Of The Week” for the week of Sept. 7, 2022.
Otolith Receives ISO 13485 Certification for Medical Devices Quality Management Systems from BSI
This is an important milestone for medical device companies.
Selected as Top Five Finalist for the MedTech Innovator Execution Award Competition
The selection was made during the pre-conference virtual live stream on September 22, 2021.
NASA iTech 2020 Cycle 1 Winner
Through NASA’s iTech initiative, the agency discovers and assesses technologies that could help it accomplish future missions. Otolith Labs was one of the three winning teams in 2020.
Otolith Labs is Proud to Sponsor VeDa
The Vestibular Disorder Association provides educational and support resources to people suffering from chronic vertigo and vestibular disorders.
Increased Bone Conducted Vibration Reduces Motion Sickness
Results from a study testing bone conductive vibrations proved the device decreases nausea from motion sickness.
Otolith Labs Interviewed on This Week In Hearing Episode
Dr. Robert Traynor interviews Otolith CEO and CSO on This Week In Hearing, presented by Hearing Health & Technology Matters.
Development of Therapeutic Headband for Vertigo Sufferers
Washington Business Journal talks about Otolith Labs’ plan for FDA approval and the funding necessary to get there.
Recognition
Recognition
Medtech Innovator Accelerator
Halcyon Incubator
NASA iTech 2020 Cycle 1 Winner
Press Releases
━ Feb. 13, 2025 ━
Otolith Labs Announces Data Demonstrating Otolith Technology Effectiveness on Cybersickness from Virtual Reality in Exploratory Study
━ May 7, 2024 ━
Otolith Labs Rounds Out Executive Team with Appointment of Kevin Franck, PhD, MBA as Chief Clinical Officer
━ Feb. 21, 2024 ━
Otolith Labs Expands Leadership Team with the Appointment of Dan Wagner as its Chief Commercial Officer and Raphael Michel to its Board of Directors
━ June 24, 2021 ━
Otolith Labs Receives “Breakthrough Device” Designation from FDA for Its Prescription Treatment for Vertigo
200 Massachusetts Ave NW, Floor 7, Washington, DC 20001
© 2024 Otolith Labs, Inc.